--- title: "CDT Equity (CDT) news: reverse split and delisting" url: "https://aibio.space/companies/cdt-equity/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CDT reverse split, delisting, convertible notes and Nasdaq notice news: CDT Equity seeks votes on reverse splits up to 1-for-1,000 and Astor note shares." --- CDT CDT Equity Inc. NASDAQ · United States # CDT Equity (CDT) news CDT reverse split, delisting and convertible notes news Listings · 2026-10-27 ## [CDT Equity seeks votes on reverse splits up to 1-for-1,000 and Astor note shares](https://aibio.space/news/cdt-equity-seeks-votes-reverse-splits-up-1-1-000-astor-note-shares/) The November 12, 2026 meeting will vote on issuing stock under the Astor notes and warrants, and on reverse splits of up to 1-for-1,000. There were 9,322,805 shares outstanding on the October 23, 2026 record date. ## Latest CDT Equity news 1. 2026-10-13 Debt Financing [CDT Equity gets $3,000,000 first tranche of $6,750,000 convertible note](https://aibio.space/news/cdt-equity-gets-3-000-000-first-tranche-6-750-000-convertible-note/) The first tranche brought in $3,000,000, with net proceeds of $2,869,850 after closing fees. The lender can convert at 70% of the lowest recent close, with a floor of $0.18354, and the company reported $747,000 of cash at June 30, 2026. 2. 2026-09-25 Listings [CDT Equity to do 1-for-25 reverse stock split on Nasdaq](https://aibio.space/news/cdt-equity-do-1-25-reverse-stock-split-nasdaq/) The split takes effect September 28, 2026, to keep the company in compliance with the Nasdaq bid-price rule, and trading on the split-adjusted basis starts September 29. 3. 2026-09-14 Debt Financing [CDT Equity issues $2,126,250 secured convertible note to J.J. Astor & Co.](https://aibio.space/news/cdt-equity-issues-2-126-250-secured-convertible-note-j-j-astor-co/) The note matures March 1, 2027 and is payable in 24 weekly installments of $88,593.75. The lender can convert at the greater of 70% of the lowest volume-weighted average price or a $0.05 floor. 4. 2026-08-31 Debt Financing [CDT Equity issues $541,620 senior secured convertible note to J.J. Astor](https://aibio.space/news/cdt-equity-issues-541-620-senior-secured-convertible-note-j-j-astor/) The note was issued on August 31, 2026 and repaid in full on September 4, 2026. It came with warrants for 237,000 shares. 5. 2026-07-31 Debt Financing [CDT Equity raises J.J. Astor note to $2,266,650 at 19% interest](https://aibio.space/news/cdt-equity-raises-j-j-astor-note-2-266-650-19-percent-interest/) CDT Equity and J.J. Astor & Co. signed a second amendment on July 31, 2026 that raised the note's principal to $2,266,650 at 19% interest. Weekly installments of $104,187.65 start August 19, 2026, and the lender may convert part of the balance into common stock. 6. 2026-07-16 Listings [CDT Equity to do 1-for-10 reverse stock split effective July 17](https://aibio.space/news/cdt-equity-do-1-10-reverse-stock-split-effective-july-17/) The split takes effect July 17, 2026 and trades on a split-adjusted basis from July 20, reducing outstanding shares to approximately 631,077. 7. 2026-06-30 Debt Financing [CDT Equity closes second tranche of its $1,460,000 convertible loan](https://aibio.space/news/cdt-equity-closes-second-tranche-1-460-000-convertible-loan/) J.J. Astor & Co. is the lender on a senior secured convertible note with a principal amount of $1,971,000, amended on June 30, 2026. The company receives $1,460,000 in two tranches, and repays the loan in weekly installments of $82,125 starting July 10, 2026. 8. 2026-06-11 Debt Financing [CDT Equity repays legacy notes and signs $1,460,000 JJ Astor loan](https://aibio.space/news/cdt-equity-repays-legacy-notes-signs-1-460-000-jj-astor-loan/) CDT Equity agreed to pay off its Alliance Global Partners and Ascent Partners loans and signed a loan of up to $1,460,000 with JJ Astor & Co, which it says is now its only loan facility. Its 2025 net loss was $39.2 million. 9. 2026-05-28 Listings [CDT Equity gets Nasdaq notice over late first-quarter 10-Q](https://aibio.space/news/cdt-equity-gets-nasdaq-notice-late-first-quarter-10/) The company did not file its quarterly report for the period ended March 31, 2026 on time, and it has until July 20, 2026 to submit a plan to regain compliance. 10. 2025-08-14 Distress [CDT Equity, formerly Conduit Pharmaceuticals, says Q1 2025 financials should not be relied on](https://aibio.space/news/cdt-equity-formerly-conduit-pharmaceuticals-says-q1-2025-financials/) The company says $0.4 million of milestone payments to Sarborg Limited were booked as research and development expense but should have been an acquired diagnostic asset. It plans to amend its first-quarter Form 10-Q. 11. 2025-04-01 Listings [Conduit Pharmaceuticals (now CDT Equity) says it meets Nasdaq equity standard](https://aibio.space/news/conduit-pharmaceuticals-now-cdt-equity-says-meets-nasdaq-equity/) The company reported pro forma stockholders' equity of $2.8 million as of March 31, 2025, against a $2.5 million minimum. It also said it meets the market value of publicly held securities rule. 12. 2025-02-19 Listings [Conduit Pharmaceuticals (now CDT Equity) repays Nirland note as Nasdaq cites more delisting grounds](https://aibio.space/news/conduit-pharmaceuticals-now-cdt-equity-repays-nirland-note-nasdaq/) Nasdaq's staff found on February 12, 2025 that Conduit Pharmaceuticals had not met two market value requirements within the 180-day grace period. The next day the company repaid the last $926,149 of a senior secured note to Nirland Limited, which it says was meant to help with the Nasdaq deficiencies. ## CDT Equity at a glance - **Ticker**: CDT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $747,000 ### Related companies - [Lotus Pharmaceuticals](https://aibio.space/companies/lotus-pharmaceuticals/) OTC: LTUS - [Ionis Pharmaceuticals](https://aibio.space/companies/ionis-pharmaceuticals/) NASDAQ: IONS - [Assembly Biosciences](https://aibio.space/companies/assembly-biosciences/) NASDAQ: ASMB - [Ocean Biomediacal](https://aibio.space/companies/ocean-biomediacal/) OTC: OCEA - [Cell Source](https://aibio.space/companies/cell-source/) OTC: CLCS - [Alphatec Holdings](https://aibio.space/companies/alphatec/) NASDAQ: ATEC - [Incyte](https://aibio.space/companies/incyte/) NASDAQ: INCY - [LianBio](https://aibio.space/companies/lianbio/) OTC: LIANY ### Also on NASDAQ - [Parabilis Medicines](https://aibio.space/companies/parabilis-medicines/) PBLS - [MARAVAI LIFESCIENCES HOLDINGS, INC.](https://aibio.space/companies/maravai-lifesciences/) MRVI - [Coya Therapeutics](https://aibio.space/companies/coya-therapeutics/) COYA - [NewcelX](https://aibio.space/companies/newcelx/) NCEL - [Artelo Biosciences](https://aibio.space/companies/artelo-biosciences/) ARTL - [Guardant Health](https://aibio.space/companies/guardant-health/) GH ## What CDT Equity does CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., describes itself as a data-driven pharmaceutical development company. It seeks to identify and advance clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies, using solid-form chemistry and co-crystallization at its Cambridge facilities to improve drug properties and extend patent life. Its pipeline targets autoimmune disorders, idiopathic male infertility, dermatology and animal health. The company holds a license from AstraZeneca covering the HK-4 Glucokinase Activator cocrystal AZD1656 and AZD5658 in all indications, and AZD5904 for idiopathic male infertility. A collaboration with Sarborg Limited applies AI-powered signature analysis to find new uses for existing compounds, and a partnership with Manoira Corporation extends the portfolio into animal health. The company says it intends to seek exits through third-party license deals after successful in vitro and in vivo preclinical studies. | Product or program | What it is | Stage | |---|---|---| | AZD1656 cocrystal | Solid-form HK-4 Glucokinase Activator cocrystal for autoimmune disorders | pending patent applications; initial pre-clinical and clinical testing by AstraZeneca | | AZD5904 | Myeloperoxidase inhibitor licensed for idiopathic male infertility | initial pre-clinical and clinical testing by AstraZeneca | Summarised from the company's [10-K filed Apr 15, 2026](https://www.sec.gov/Archives/edgar/data/1896212/000149315226016858/form10-k.htm). ## CDT Equity annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$5.1 million](https://www.sec.gov/Archives/edgar/data/1896212/000149315226016858/) | [$3.4 million](https://www.sec.gov/Archives/edgar/data/1896212/000149315226016858/) | | Net income (loss) | [-$39.2 million](https://www.sec.gov/Archives/edgar/data/1896212/000149315226016858/) | [-$17.8 million](https://www.sec.gov/Archives/edgar/data/1896212/000149315226016858/) | | Cash from operations | [-$15.6 million](https://www.sec.gov/Archives/edgar/data/1896212/000149315226016858/) | [-$9.7 million](https://www.sec.gov/Archives/edgar/data/1896212/000149315226016858/) | | Cash and equivalents | [$1.5 million](https://www.sec.gov/Archives/edgar/data/1896212/000149315226037458/) | [$554,000](https://www.sec.gov/Archives/edgar/data/1896212/000149315226016858/) | | Short-term investments | | [$600,000](https://www.sec.gov/Archives/edgar/data/1896212/000164117225024123/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $747,000. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about CDT Equity Did CDT Equity do a reverse stock split? Our latest story on this, dated Oct 27, 2026: "CDT Equity seeks votes on reverse splits up to 1-for-1,000 and Astor note shares". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cdt-equity-seeks-votes-reverse-splits-up-1-1-000-astor-note-shares/). Was CDT Equity delisted? Our latest story on this, dated Feb 19, 2025: "Conduit Pharmaceuticals (now CDT Equity) repays Nirland note as Nasdaq cites more delisting grounds". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/conduit-pharmaceuticals-now-cdt-equity-repays-nirland-note-nasdaq/). Has CDT Equity sold convertible notes? Our latest story on this, dated Oct 13, 2026: "CDT Equity gets $3,000,000 first tranche of $6,750,000 convertible note". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cdt-equity-gets-3-000-000-first-tranche-6-750-000-convertible-note/). Has CDT Equity received a Nasdaq deficiency notice? Our latest story on this, dated May 28, 2026: "CDT Equity gets Nasdaq notice over late first-quarter 10-Q". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cdt-equity-gets-nasdaq-notice-late-first-quarter-10/). What is the ticker symbol of CDT Equity? CDT Equity Inc. trades under the ticker CDT on NASDAQ. Where is CDT Equity listed? CDT Equity Inc. is listed on NASDAQ. What is the SEC CIK of CDT Equity? The SEC Central Index Key (CIK) for CDT Equity Inc. is 1896212. Its filings are on SEC EDGAR. How many shares does CDT Equity have outstanding? 786,670 shares as of 2026-08-12, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is CDT Equity listed under? Our directory records CDT Equity Inc. under United States. What does CDT Equity do? Our directory classifies CDT Equity Inc. as: Mixed biopharma / AI and treasury. This is a directory classification, not a description of the pipeline. What is the ISIN of CDT Equity? The ISIN recorded for CDT Equity Inc. is US20678X7003. Does aibio.space cover CDT Equity? aibio.space lists CDT Equity Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is CDT Equity incorporated? SEC records list its state or country of incorporation as DE. What does CDT Equity develop? CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., describes itself as a data-driven pharmaceutical development company. It seeks to identify and advance clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies, using solid-form chemistry and co-crystallization at its Cambridge facilities to improve drug properties and extend patent life. What is AZD1656 cocrystal from CDT Equity? AZD1656 cocrystal: Solid-form HK-4 Glucokinase Activator cocrystal for autoimmune disorders Stage: pending patent applications; initial pre-clinical and clinical testing by AstraZeneca. ## Investor discussion: CDT Equity Members talk about CDT Equity (CDT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at CDT Equity, newest first. Each line links the filing it comes from. 1. 2026-10-27 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226048693/formdef14a.htm) 2. 2026-10-16 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226047422/formpre14a.htm) 3. 2026-10-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226046738/form8-k.htm) 4. 2026-09-25 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226044248/ex99-1.htm) 5. 2026-09-01 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226041016/form8-k.htm) 6. 2026-08-11 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226036998/formdef14a.htm) 7. 2026-07-31 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226035687/formpre14a.htm) 8. 2026-07-29 Financings Reported a financing. SEC Form 8-K (Items 3.02). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226035202/form8-k.htm) 9. 2026-07-16 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226033455/ex99-1.htm) 10. 2026-06-29 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226031093/form8-k.htm) 11. 2026-06-16 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226028909/ex99-1.htm) 12. 2026-05-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/ex99-1.htm) 13. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226023832/formnt10-q.htm) 14. 2026-04-22 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226018405/forms-3.htm) 15. 2026-04-02 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226014923/form424b5.htm) 16. 2026-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226014626/formnt10-k.htm) 17. 2026-03-25 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226012538/ex99-1.htm) 18. 2026-03-18 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226011270/form8-k.htm) 19. 2026-03-06 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226009143/formdef14a.htm) 20. 2026-02-24 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226007899/formpre14a.htm) 21. 2026-02-24 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226007906/form8-k.htm) 22. 2026-01-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226003244/form8-k.htm) 23. 2026-01-02 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315226000143/ex99-1.htm) 24. 2025-12-12 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315225027489/form8-k.htm) 25. 2025-10-09 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000149315225017533/ex99-1.htm) 26. 2025-08-14 Legal Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000164117225023840/form8-k.htm) 27. 2025-06-09 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000164117225014322/ex99-1.htm) 28. 2025-05-16 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000164117225011183/ex99-1.htm) 29. 2025-05-06 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000164117225008854/form8-k.htm) 30. 2025-04-25 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1896212/000164117225006224/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CDT on TradingView](https://www.tradingview.com/symbols/NASDAQ-CDT/). ## SEC filings and registration - **SEC name**: CDT Equity Inc. - **CIK**: 1896212 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CDT (Nasdaq), CDTTW (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 4851 TAMIAMI TRAIL NORTH, NAPLES, FL, 34103 - **Phone**: (646) 491 9132 - **Shares outstanding**: 786,670 as of 2026-08-12 (10-Q filed 2026-08-12) - **Former names**: CONDUIT PHARMACEUTICALS INC.; Murphy Canyon Acquisition Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1896212/000149315226046738/form8-k.htm) filed 2026-10-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1896212/000149315226044248/form8-k.htm) filed 2026-09-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1896212/000149315226043398/form8-k.htm) filed 2026-09-18 - [S-1](https://www.sec.gov/Archives/edgar/data/1896212/000149315226041808/forms-1.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1896212/000149315226041533/form8-k.htm) filed 2026-09-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1896212/000149315226041016/form8-k.htm) filed 2026-09-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1896212/000149315226040929/form8-k.htm) filed 2026-09-01 - [10-Q](https://www.sec.gov/Archives/edgar/data/1896212/000149315226037458/form10-q.htm) filed 2026-08-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001896212), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details CDT Equity Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CDT, recorded under United States. The directory classifies it as Mixed biopharma / AI and treasury. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: CDT Equity Inc. - **Ticker**: CDT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Mixed biopharma / AI and treasury - **ISIN**: US20678X7003 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CDT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cdt-equity/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CDT Equity (CDT) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/cdt-equity/